Manas AI Launches to Transform Discovery of Novel Cancer Medicines
Cofounded by Dr. Siddhartha Mukherjee and Reid Hoffman, Manas AI leverages proprietary AI, generative computational chemistry ...
Imaging research on monoclonal antibodies sheds light on protein dynamics for biopharmaceutical development
Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments ...
Metastatic Breast Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight
DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...
Insider Monkey5d
Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies
On January 27, the company announced improvements to its RADR® AI platform aimed at accelerating and optimizing the development of antibody-drug conjugates (ADCs). ADC is a process of creating ...
Medindia2d
Update on regulatory review of lecanemab for treatment of early Alzheimer's disease in the European Union
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for Human Use (CHMP) to consider two ...
technologynetworks1d
Improving Efficiency in Drug Discovery and Development
This article explores methods to enhance efficiency in the drug discovery and development pipeline, focusing on optimizing ...
Le Lézard5d
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
BioArctic AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application (sBLA) for Leqembi as a once ...
Pharmaceutical Technology on MSN2d
Leveragen and Moonlight Bio unite for T-cell therapy development
Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for ...
Le Lézard3d
IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO) by the Singapore Health Sciences Authority (HSA)
IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced ...
pharmaphorum1d
Recursion, Exscientia, and AI drug discovery’s moment of truth
Abcellera, for example, designed Lily’s COVID antibody ... business of drug discovery, find promising targets, and then sell them to pharma to carry out the expensive process of development ...